Abstract
1 A double-blind placebo-controlled study of fluvoxamine and imipramine was performed in a group of depressed patients. Twenty-two patients received fluvoxamine (mean dose 101 mg/day), 25 received imipramine (mean dose 127 mg/day) and 22 received placebo.
2 Apart from an increase in the SGOT and SGPT values of four imipramine patients, no statistically significant changes in haematology or urinalysis were judged to be medically relevant. Fluvoxamine exhibited fewer anticholinergic side effects than imipramine.
3 Both fluvoxamine treated patients and imipramine-treated patients exhibited a statistically significant improvement at the end of the 28-day treatment period with respect to the placebo patients, as measured using the Hamilton Rating Scale for Depression, and the Clinical Global Impression Scale. Evaluations of the results of the Beck Depression Inventory and the Profile of Mood States revealed a statistically significant improvement for imipramine patients with respect to placebo at week 4, but not for fluvoxamine patients. It is postulated on the basis of quantitative pharmaco-EEG findings, that the slight superiority of imipramine over fluvoxamine was due to underdosing of the latter.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beck A. T., Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974;7(0):151–169. doi: 10.1159/000395074. [DOI] [PubMed] [Google Scholar]
- Claassen V., Davies J. E., Hertting G., Placheta P. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol. 1977 Aug;60(4):505–516. doi: 10.1111/j.1476-5381.1977.tb07528.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Coppen A., Prange A. J., Jr, Whybrow P. C., Noguera R. Abnormalities of indoleamines in affective disorders. Arch Gen Psychiatry. 1972 May;26(5):474–478. doi: 10.1001/archpsyc.1972.01750230084016. [DOI] [PubMed] [Google Scholar]
- Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278–296. doi: 10.1111/j.2044-8260.1967.tb00530.x. [DOI] [PubMed] [Google Scholar]
- Itil T. M., Cora R., Akpinar S., Herrmann W. M., Patterson C. J. "Psychotropic" action of sex hormones: computerized EEG in establishing the immediate CNS effects of steroid hormones. Curr Ther Res Clin Exp. 1974 Nov;16(11):1147–1170. [PubMed] [Google Scholar]
- Itil T. M., Herrmann W. M., Akpinar S. Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):221–233. [PubMed] [Google Scholar]
- Itil T. M., Polvan N., Hsu W. Clinical and EEG effects of GB-94, a "tetracyclic" antidepressant (EEG model in discovery of a new psychotropic drug). Curr Ther Res Clin Exp. 1972 Jul;14(7):395–413. [PubMed] [Google Scholar]
- Itil T., Gannon P., Cora R., Polvan N., Akpinar S., Elveris F., Eskazan E. SCH-12,041, a new anti-anxiety agent (quantitative pharmaco-electroencephalography and clinical trials). Behav Neuropsychiatry. 1972 Aug-Sep;4(4-5):15–24. [PubMed] [Google Scholar]
- Maas J. W. Biogenic amines and depression. Biochemical and pharmacological separation of two types of depression. Arch Gen Psychiatry. 1975 Nov;32(11):1357–1361. doi: 10.1001/archpsyc.1975.01760290025002. [DOI] [PubMed] [Google Scholar]